Prothena Appoints Chad J. Swanson as Chief Development Officer

By Bobby Samwell • Saturday, September 28 06:01 • Permanent Link

Prothena Corporation PLC (NASDAQ:PRTA) has announced changes to its leadership team with the appointment of Chad J. Swanson, Ph.D., as the Chief Development Officer. Dr. Swanson, who has over 20 years of industry experience, will lead the clinical development and medical functions at Prothena.

Prior to his appointment, Dr. Swanson was the Senior Vice President and Head of Clinical Development at Prothena since January 2023. He previously served as the Executive Director of Clinical Research in the Alzheimer's disease brain health group at Eisai, Inc. During his tenure at Eisai, Dr. Swanson led the innovative phase 2 dose finding study for lecanemab, which resulted in the accelerated approval of leqembi™ in January 2023.

Meanwhile, Hideki Garren, M.D., Ph.D., who previously held the position of Chief Medical Officer at Prothena, will be pursuing an opportunity at a large pharmaceutical company to lead a global product development division.

Dr. Swanson's appointment comes at a critical time for Prothena as the company anticipates meaningful clinical readouts across multiple programs in the next nine months and beyond. Prothena is focused on developing potential best-in-class therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases.

Prothena's pipeline includes programs for the potential treatment of diseases such as AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases.

The company expressed confidence in Dr. Swanson's ability to lead the robust research and development pipeline, emphasizing his deep clinical and research experience in neuroscience.

These changes in the leadership team reflect Prothena's strategic approach to advancing its portfolio of investigational therapeutics and addressing unmet medical needs in the field of neurodegenerative and rare peripheral amyloid diseases.

As Prothena moves forward with these leadership changes, the company remains focused on leveraging its scientific expertise in protein dysregulation to drive advancements in therapeutic candidates and novel targets, with the ultimate goal of positively impacting millions of patients and their families worldwide. As a result of these announcements, the company's shares have moved -0.4% on the market, and are now trading at a price of $20.05. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.